Last reviewed · How we verify
Pembrolizumab or Nivolumab
Pembrolizumab or Nivolumab is a Small molecule drug developed by Intergruppo Melanoma Italiano. It is currently in Phase 2 development. Also known as: Keytruda or Opdivo.
At a glance
| Generic name | Pembrolizumab or Nivolumab |
|---|---|
| Also known as | Keytruda or Opdivo |
| Sponsor | Intergruppo Melanoma Italiano |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (PHASE2)
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer (PHASE2)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (PHASE1)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial (PHASE2)
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (PHASE1)
- Drug Screening Using Novel IMD in Renal Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pembrolizumab or Nivolumab CI brief — competitive landscape report
- Pembrolizumab or Nivolumab updates RSS · CI watch RSS
- Intergruppo Melanoma Italiano portfolio CI
Frequently asked questions about Pembrolizumab or Nivolumab
What is Pembrolizumab or Nivolumab?
Pembrolizumab or Nivolumab is a Small molecule drug developed by Intergruppo Melanoma Italiano.
Who makes Pembrolizumab or Nivolumab?
Pembrolizumab or Nivolumab is developed by Intergruppo Melanoma Italiano (see full Intergruppo Melanoma Italiano pipeline at /company/intergruppo-melanoma-italiano).
Is Pembrolizumab or Nivolumab also known as anything else?
Pembrolizumab or Nivolumab is also known as Keytruda or Opdivo.
What development phase is Pembrolizumab or Nivolumab in?
Pembrolizumab or Nivolumab is in Phase 2.
Related
- Manufacturer: Intergruppo Melanoma Italiano — full pipeline
- Also known as: Keytruda or Opdivo
- Compare: Pembrolizumab or Nivolumab vs similar drugs
- Pricing: Pembrolizumab or Nivolumab cost, discount & access